{"id":"ym150","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, YM150 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"YM150 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:18.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00902928","phase":"PHASE2, PHASE3","title":"A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2009-04","conditions":"Venous Thromboembolism, Arthroplasty, Replacement, Hip","enrollment":1992},{"nctId":"NCT00994292","phase":"PHASE2","title":"Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2009-09","conditions":"Acute Coronary Syndrome","enrollment":1276},{"nctId":"NCT01405989","phase":"PHASE1","title":"To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01","conditions":"Pharmacokinetics of Darexaban and Metabolites, Healthy Subjects","enrollment":26},{"nctId":"NCT01657981","phase":"PHASE1","title":"A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2007-02","conditions":"Pharmacokinetics, Healthy Male Subjects","enrollment":6},{"nctId":"NCT01655056","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2006-06","conditions":"Pharmacokinetics, Pharmacodynamics, Healthy Subjects","enrollment":82},{"nctId":"NCT01409603","phase":"PHASE1","title":"To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01","conditions":"Pharmacodynamic Interaction, Healthy Subjects","enrollment":26},{"nctId":"NCT01406002","phase":"PHASE1","title":"To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01","conditions":"Pharmacokinetics of Darexaban and Metabolites, Healthy Subjects","enrollment":26},{"nctId":"NCT00595426","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05","conditions":"Arthroplasty, Replacement, Knee","enrollment":685},{"nctId":"NCT01409616","phase":"PHASE1","title":"To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Pharmacodynamic Interaction, Healthy Subjects","enrollment":100},{"nctId":"NCT00353678","phase":"PHASE2","title":"Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-06","conditions":"Thromboembolism","enrollment":1141},{"nctId":"NCT01514812","phase":"PHASE1","title":"A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Healthy, Pharmacokinetic of Digoxin","enrollment":24},{"nctId":"NCT01514825","phase":"PHASE1","title":"A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-11","conditions":"Healthy Elderly Subject, Pharmacokinetic of YM150","enrollment":36},{"nctId":"NCT00448214","phase":"PHASE2","title":"Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-03","conditions":"Atrial Fibrillation","enrollment":448},{"nctId":"NCT00408239","phase":"PHASE2","title":"Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-12","conditions":"Thromboembolism","enrollment":367},{"nctId":"NCT01424332","phase":"PHASE1","title":"To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Pharmacodynamic and Pharmacokinetic Interaction, Healthy Subjects","enrollment":24},{"nctId":"NCT00938730","phase":"PHASE2","title":"A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-06","conditions":"Atrial Fibrillation","enrollment":1280},{"nctId":"NCT00937820","phase":"PHASE3","title":"Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-06","conditions":"Venous Thromboembolism","enrollment":87},{"nctId":"NCT00942435","phase":"PHASE3","title":"A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-06","conditions":"Venous Thromboembolism","enrollment":156},{"nctId":"NCT00937911","phase":"PHASE3","title":"Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-06","conditions":"Venous Thromboembolism","enrollment":101},{"nctId":"NCT01028950","phase":"PHASE3","title":"YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":52},{"nctId":"NCT00917254","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":369},{"nctId":"NCT00913120","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":610},{"nctId":"NCT01125657","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":"Healthy Volunteer, Pharmacokinetics of YM150","enrollment":44},{"nctId":"NCT01125670","phase":"PHASE1","title":"A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":"Healthy Volunteer, Pharmacokinetics of YM150","enrollment":24},{"nctId":"NCT01118559","phase":"PHASE1","title":"A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-11","conditions":"Healthy, Pharmacokinetics of YM150","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["darexaban"],"phase":"phase_3","status":"active","brandName":"YM150","genericName":"YM150","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YM150 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}